References

Cure Arthritis Naturally

Cure Arthritis Naturally

Get Instant Access

Abrams, J.R., Lebwohl, M.G., Guzzo, C.A. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest 103, 1243.

Antoni, C., Krueger, G.G., De, V.K., Birbara, C., et al. 2005. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150.

Aringer, M., Graninger, W.B., Steiner, G., et al. 2004. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50, 3161.

Asadullah, K., Sabat, R., Friedrich, M., et al. 2004. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr. Drug Targets Inflamm. Allergy 3, 185.

Bachelez, H., Flageul, B., Dubertret, L., et al. 1998. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. 11, 53.

Bagel, J., Garland, W.T., Breneman, D., et al. 1998. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J. Am. Acad. Dermatol. 38, 938.

Bain, B., Brazil, M. 2003. Adalimumab. Nat. Rev. Drug Discov. 2, 693.

Barry, J., Kirby, B. 2004. Novel biologic therapies for psoriasis. Expert Opin. Biol. Ther. 4, 975.

Bayes, M., Rabasseda, X., Prous, J.R. 2003. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 25, 483.

Bianchi, L., Bergamin, A., de Felice, C., et al. 2005. Remission and time of resolution of nail psoriasis during infliximab therapy. J. Am. Acad. Dermatol. 52, 736.

Boye, J., Elter, T., Engert, A. 2003. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14, 520.

Braun, J., Sieper, J. 2003a. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther. 3, 141.

Braun, J., Sieper, J. 2003b. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. Bio. Drugs 17, 187.

Carpenter, P.A., Lowder, J., Johnston, L., et al. 2005. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 11, 465.

Cassetty, C.T., Alexis, A.F., Shupack, J.L., et al. 2005. Ale-facept in the treatment of psoriatic nail disease: a small case series. J. Am. Acad. Dermatol. 52, 1101.

Cather, J.C., Menter, A. 2005. Efalizumab: continuous therapy for chronic psoriasis. Expert Opin. Biol. Ther. 5, 393.

Charles, P.J., Smeenk, R.J., De Jong, J., et al. 2000. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43, 2383.

Chew, A.L., Bennett, A., Smith, C.H., et al. 2004. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br. J. Dermatol. 151, 492.

Christou, N.V., Mannick, J.A., West, M.A., et al. 1987. Lymphocyte macrophage interactions in the response to surgical infections. Arch. Surg. 122, 239.

Daikh, D.I., Wofsy, D. 1999. Effects of anti-B7 monoclonal antibodies on humoral immune responses. J. Autoimmun. 12, 101.

Davenport, C.M., McAdams, H.A., Kou, J. 2002. Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis. Int. Immunopharmacol. 2, 653.

Davidson, A., Diamond, B., Wofsy, D., et al. 2005. Block and tackle: CTLA4Ig takes on lupus. Lupus 14, 197.

Davis, C.B., Gillies, S.D. 2003. Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol. Immun. 52, 297.

Davis, J.C., Jr., Totoritis, M.C., Rosenberg, J., et al. 2001. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. 28, 95.

De Bandt, M., Sibilia, J., Le Loet, X., et al. 2005. Club Rhumatismes et Inflammation, Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. 7, R545.

Debandt, M., Vittecoq, O., Descamps, V., et al. 2003. Anti-TNF-alpha-induced systemic lupus syndrome. Clin. Rheumatol. 22, 56.

Dinarello, C.A. 2004. Blocking IL-1 in systemic inflammation. J. Exp. Med. 201, 1355.

This paper highlights the central role of IL-1 in systemic autoimmune diseases with emphasis on systemic onset juvenile idiopathic arthritis and the therapeutic perspective of IL-1 blocking.

Edwards, J.C., Szczepanski, L., Szechinski, J. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572.

Eklund, J.W., Kuzel, T.M. 2005. Denileukin diftitox: a concise clinical review. Expert Rev. Anticancer Ther. 5, 33.

Emmi, L., Chiarini, F. 2002. The role of intravenous immuno-globulin therapy in autoimmune and inflammatory disorders. Neurol. Sci. 23 (Suppl. 1), S1.

Eriksson, C., Engstrand, S., Sundqvist, K.G., et al. 2005. Auto-antibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann. Rheum. Dis. 64, 403.

Fautrel, B., Foltz, V., Frances, C., et al. 2002. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum. 46, 1408.

Feldmann, M., Steinman, L. 2005. Design of effective immunotherapy for human autoimmunity. Nature 435, 612.

This comprehensive review describes the current status of immunotherapeutics for human autoimmune diseases.

Finck, B.K., Linsley, P.S., Wofsy, D. 1994. Treatment of murine lupus with CTLA4Ig. Science 265, 1225.

Finucane, K.A., Archer, C.B. 2005. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoanti-bodies in systemic lupus erythematosus. Clin. Exp. Dermatol. 30, 201.

Furst, D.E., Schiff, M.H., Fleischmann, R.M., et al. 2003. Ad-alimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheu-matic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30, 2563.

Ghoreschi, K., Thomas, P., Breit, S., et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9, 40.

Gillies, S.D., Lan, Y., Williams, S., et al. 2005. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105, 3972.

Gniadecki, R., Zachariae, C., Calverley, M. 2002. Trends and developments in the pharmacological treatment of psoriasis. Acta Derm. Venereol. 82, 401.

Goffe, B., Cather, J.C. 2003. Etanercept: an overview. J. Am. Acad. Dermatol. 49, S105.

This review summarizes the structure and mechanism of action of etanercept as well as therapeutic results derived from clinical trials with etanercept involving patients with psoriasis.

Gordon, K.B., Valentine, J. 2004. The efficacy of alefacept in the treatment of chronic plaque psoriasis. J. Cutan. Med. Surg. 8 (Suppl. 2), 3.

Gottenberg, J.E., Guillevin, L., Lambotte, O., et al. 2005. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64, 913.

Gottlieb, A.B. 2004. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol. Ther. 17, 401.

Gottlieb, A.B. 2005. Psoriasis: emerging therapeutic strategies. Nat. Rev. Drug Discov. 4, 19.

Gottlieb, A.B., Chaudhari, U., Mulcahy, L.D., et al. 2003. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. 48, 829.

Gottlieb, A.B., Evans, R., Li, S., et al. 2004a. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534.

Gottlieb, A.B., Gordon, K.B., Lebwohl, M.G., et al. 2004b. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. 3, 614.

Gottlieb, A.B., Kang, S., Linden, K.G., et al. 2004c. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin. Immunol. 111, 28.

Gottlieb, A.B., Lebwohl, M., Totoritis, M.C., et al. 2002. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J. Am. Acad. Dermatol. 47, 692.

Gribetz, C.H., Blum, R., Brady, C., et al. 2005. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J. Am. Acad. Dermatol. 53, 73.

Hengstman, G.J., van den Hoogen, F.H., Barrera, P., et al. 2003. Successful treatment of dermatomyositis and poly-myositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur. Neurol. 50, 10.

Herrmann, G., Hunzelmann, N., Engert, A. 2003. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br. J. Dermatol. 148, 602.

High, W.A., Muldrow, M.E., Fitzpatrick, J.E. 2005. Cutaneous lupus erythematosus induced by infliximab. J. Am. Acad. Dermatol. 52, E5.

Hirche, D., Rubbert, A., Lunau, L., et al. 2005. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab. Br. J. Dermatol. 152, 1062.

Hunter, C.A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521.

Ibanez, C., Montoro-Ronsano, J.B. 2003. Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. Curr Pharm Biotechnol 4, 239.

This paper is a review on the variety of molecular actions of intravenous immunoglubulins with focus on autoimmune disorders.

Imperato, A.K., Bingham III, C.O., Abramson, S.B. 2004. Overview of benefit/risk of biological agents. Clin. Exp. Rheumatol. 22, S108.

Iyer, S., Yamauchi, P., Lowe, N.J. 2002. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br. J. Dermatol. 146, 118.

Kagi, M.K., Heyer, G. 2001. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis. Brit. J. Dermatol. 145, 350.

Kalunian, K.C., Davis, J.C., Jr., Merrill, J.T., et al. 2002. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 3251.

Kauffman, C.L., Aria, N., Toichi, E., et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123, 1037.

Keystone, E., Haraoui, B. 2004. Adalimumab therapy in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 30, 349.

Kourbeti, I.S., Boumpas, D.T. 2005. Biological therapies of autoimmune diseases. Curr. Drug Targets Inflamm. Allergy 4, 41.

Krueger, G.G., Callis, K.P. 2003. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol. 49, S87.

Krueger, G.G., Ellis, C.N. 2003. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Brit. J. Dermatol. 148, 784.

Krueger, J.G., Walters, I.B., Miyazawa, M., et al. 2000. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43, 448.

Labioche, I., Liozon, E., Weschler, B., et al. 2004. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 43, 531.

Leandro, M.J., Edwards, J.C., Cambridge, G., et al. 2002. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673.

Lebwohl, M., Christophers, E., Langley, R., et al. 2003. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139, 719.

Lehnen, M., Franckson, T., Knab, J., et al. 2005. Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis. Br. J. Dermatol. 153, 212.

Leonard, J.P., Coleman, M., Ketas, J.C., et al. 2004. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. 10, 5327.

Leonardi, C.L., Papp, K.A., Gordon, K.B., et al. 2005. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J. Am. Acad. Dermatol. 52, 425.

Leone, G., Rolston, K., Spaulding, G. 2003. Alefacept for chronic plaque psoriasis: a selective therapy with long-lasting disease remissions and an encouraging safety profile. Dermatol. Nurs. 15, 216.

Lin, M.H., Hsu, C.K., Lee, J.Y. 2005. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch. Dermatol. 141, 680.

Llorente, L., Richaud-Patin, Y., Garcia-Padilla, C., et al. 2000. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythe-matosus. Arthritis Rheum. 43, 1790.

Looney, R.J., Anolik, J., Sanz, I. 2005. Treatment of SLE with anti-CD20 monoclonal antibody. Curr. Dir. Autoimmun. 8, 193.

Mahadevan, U., Sandborn, W.J. 2001. Infliximab for the treatment of orofacial Crohn's disease. Inflamm. Bowel Dis. 7,

Marecki, S., Kirkpatrick, P. 2004. Efalizumab. Nat. Rev. Drug. Discov. 3, 473.

Mariette, X., Ravaud, P., Steinfeld, S., et al. 2004. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum. 50, 1270.

Martin, A., Gutierrez, E., Muglia, J., et al. 2001. A multicenter dose-escalation trial with denileukin diftitox ONTAK, DAB(389)IL-2 in patients with severe psoriasis. J. Am. Acad. Dermatol. 45, 871.

Mease, P. 2004. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann. Rheum. Dis. 63, 755.

Mease, P.J., Goffe, B.S., Metz, J., et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385.

Moosig, F., Zeuner, R., Renk, C., et al. 2004. IL-1RA in refractory systemic lupus erythematosus. Lupus 13, 605.

Morse, L.G., Yarbrough, L., Hogan, D.J. 2005. Cervical cancer in a woman associated with long-term efalizumab therapy. J. Am. Acad. Dermatol. 53, 354.

Moxley, G., Ruddy, S. 1997. Immune complexes and complement. In: W.N. Kelley (Ed.), Textbook of Rheumatology. Saunders, Philadelphia.

Mrowietz, U., Zhu, K., Christophers, E. 2000. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch. Dermatol. 136, 675.

Myers, W., Christiansen, L., Gottlieb, A.B. 2005. Treatment of palmoplantar psoriasis with intramuscular alefacept. J. Am. Acad. Dermatol. 53, S127.

Najafian, N., Sayegh, M.H. 2000. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Invest. Drugs 9, 2147. This paper describes the mechanism of action of CTLA4-Ig and its efficacy in various disease models.

Nassar, G.M., Morrow, J.D., Roberts, L.J. 1994. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 269, 27631.

Nathan, C.F. 1987. Secretory products of macrophages. J. Clin. Invest. 79, 319.

Numerof, R.P., Dinarello, C.A., Asadullah, K. 2005. Cytokines as potential therapeutic targets for inflammatory skin diseases. Eur. Cytokine Netw. 16, 101.

Ormerod, A.D. 2003. Alefacept. Biogen. Curr. Opin. Invest. Drugs 4, 608.

This review summarizes the development, biochemistry and pharmacology of alefacept and its use as a biologic in patients with psoriasis.

Ostendorf, B., Iking-Konert, C., Kurz, K., et al. 2005. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 64, 630.

Owen, C.M., Harrison, P.V. 2000. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol. 25, 195.

Papp, K.A. 2004. Etanercept in psoriasis. Expert Opin. Phar-macother. 5, 2139.

Papp, K.A., Tyring, S., Lahfa, M., et al. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Der-matol. 152, 1304.

Pardo, J., Mercader, P., Mahiques, L., et al. 2005. Infliximab in the management of severe pemphigus vulgaris. Br. J. Der-matol. 153, 222.

Patel, T., Gordon, K.B. 2004. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol. Ther. 17, 427.

Posten, W., Swan, J. 2005. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch. Dermatol. 141, 759.

Prinz, J.C., Meurer, M., Reiter, C., et al. 1996. Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J. Am. Acad. Dermatol. 34, 244.

Rother, R.P., Mojcik, C.F., McCroskery, E.W. 2004. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 13, 328.

Rütter, A., Luger, T.A. 2002. Immunoglobulin: an emerging treatment for immune-mediated skin diseases. J. Am. Acad, Dermatol. Curr. Opin. Invest. Drugs 3, 713.

Saadeyh, C. 2000. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy. Arthritis Rheum. 43, S193.

Saini, R., Tutrone, W.D., Weinberg, J.M. 2005. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pi-mecrolimus. Curr. Pharm. Des. 11, 273.

Saripalli, Y.V., Gaspari, A.A. 2005. Focus on: biologics that affect therapeutic agents in dermatology. J. Drugs Der-matol. 4, 233.

Scheinfeld, N. 2004a. Adalimumab (Humira): a brief review for dermatologists. J. Dermatol. Treat. 15, 348.

Scheinfeld, N. 2004b. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J. Dermatol. Treat. 15, 280.

This paper analyses the spectrum of adverse effects associated with use of anti-TNF-a therapy based on reports published in Medline for over 5 years.

Schiff, M.H. 2000. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 59 (Suppl. 1), i103.

Schmidt, A., Robbins, J., Zic, J. 2005. Transformed mycosis fungoides developing after treatment with alefacept. J. Am. Acad. Dermatol. 53, 355.

Schottelius, A.J., Moldawer, L.L., Dinarello, C.A. 2004. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp. Dermatol. 13, 193.

Shoenfeld, Y., Krause, I. 2004. ivIg for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J. Clin. Immunol. 24, 107.

Skov, L., Kragballe, K., Zachariae, C., et al. 2003. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. 139, 1433.

Smolen, J.S., Steiner, G. 2003. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. 2, 473.

Spahn, J.D., Leung, D.Y., Chan, M.T., et al. 1999. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J. Allergy Clin. Immunol. 103, 421.

Stern, M., Herrmann, R. 2005. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 54, 11.

Strober, B.E., Siu, K., Alexis, A.F., et al. 2005. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J. Am. Acad. Dermatol. 52, 1082.

Thaci, D., Patzold, S., KauFmann, R., Boehncke, W. 2005. Treatment of psoriasis with alefacept in patients with hep atitis C infection: a report of two cases. Br. J. Dermatol. 152, 1048.

Tobin, A.M., Kirby, B. 2005. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19, 47.

Trepicchio, W.L., Ozawa, M., Walters, I.B., et al. 1999. Inter-leukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104, 1527.

Tutrone, W.D., Saini, R., Weinberg, J.M. 2004. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept. Drugs 7, 45. This paper reviews the progress of the above biologics in the treatment of psoriasis.

Viard, I., Wehrli, P., Bullani, R., et al. 1998. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490.

Wang, Y., Hu, Q., Madri, J.A., et al. 1996. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA. 93, 8563.

Wetter, D.A., Davis, M.D., Yiannias, J.A., et al. 2005. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin. Proc. 80, 41.

Winterfield, L., Menter, A., 2004. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade, Dermatol. Clin., 22, 437, ix.

Zandbelt, M.M., de Wilde, P., van Damme, P., et al. 2004. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J. Rheumatol. 1, 96.

Zelenetz, A.D. 2003. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin. Oncol. 30, 22.

Handbook of Systemic Autoimmune Diseases, Volume 5 The Skin in Systemic Autoimmune Diseases

Piercarlo Sarzi-Puttini, Andrea Doria, Giampiero Girolomoni and Annegret Kuhn, editors

Was this article helpful?

0 0
How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book


Post a comment